Participants 243 282 6
patients with moderate-to-severe asthma
Participants 559 655 4
patients with moderate-to-severe asthma who were uncontrolled on existing corticosteroid therapy
Participants 884 1156 4
Symptomatic patients (n = 428) with FEV1 of 50-85% predicted and increased symptom scores or reliever use during run-in were randomly allocated to receive either Salm/FP (50/250 microg bd) via a single Diskus inhaleror Form+Bud (12+800 microg bd) via separate Turbuhalers.
